LYMEPAK Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lymepak, and when can generic versions of Lymepak launch?
Lymepak is a drug marketed by Chartwell Pharma and is included in one NDA.
The generic ingredient in LYMEPAK is doxycycline hyclate. There are twenty-eight drug master file entries for this compound. Seventy-four suppliers are listed for this compound. Additional details are available on the doxycycline hyclate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lymepak
A generic version of LYMEPAK was approved as doxycycline hyclate by CARIBE HOLDINGS on November 8th, 1982.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LYMEPAK?
- What are the global sales for LYMEPAK?
- What is Average Wholesale Price for LYMEPAK?
Summary for LYMEPAK
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 55 |
Patent Applications: | 438 |
What excipients (inactive ingredients) are in LYMEPAK? | LYMEPAK excipients list |
DailyMed Link: | LYMEPAK at DailyMed |
Pharmacology for LYMEPAK
Drug Class | Tetracycline-class Drug |
US Patents and Regulatory Information for LYMEPAK
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chartwell Pharma | LYMEPAK | doxycycline hyclate | TABLET;ORAL | 209844-001 | Jun 15, 2018 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |